Compromise FDA Reform Bill Passes House, Adds $225 Million In User Fees For Drug Safety
This article was originally published in The Pink Sheet Daily
Executive Summary
Legislation requires patient summary of clinical trial results, but only if it can be written without being promotional.
You may also be interested in...
Strange Bedfellows: Regulators May Revive Biotech Deals And IPOs
Still mourning the loss of IPOs and desperate for exits, biotechs could be forgiven for being pessimistic. But some experts say health reform and other new regulations will renew the value of innovative drugs and revive the crucial public markets
Strange Bedfellows: Regulators May Revive Biotech Deals And IPOs
Still mourning the loss of IPOs and desperate for exits, biotechs could be forgiven for being pessimistic. But some experts say health reform and other new regulations will renew the value of innovative drugs and revive the crucial public markets
FDA Reform Bill Could Still Face Administrative Gauntlet After Enactment
Implementation of new FDA drug safety authorities may not be quick or easy if lengthy rule-making is a prerequisite to action.